Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE · Healthcare

₹1,215.00

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Neutral 54% confidence

Strong technical momentum and regulatory validation offset by severe Q1 earnings deterioration and missing fundamentals; imminent Q2…

Strongest bull point

Stock rallied 39.89% in 12 months with bullish EMA stack, RSI 64.63, and 25.09 percentage-point outperformance vs NIFTY, supported by clean FDA inspection and AAA/Stable credit rating.

Strongest bear point

Q1 FY27 showed 36% profit decline and 770 bps EBITDA margin compression despite 22% revenue growth, with 91% dividend cut signalling cash flow stress; stock trades at 52-week high with no fundamental valuation data.

Technical Forecast · next 10 trading days

Expected

₹1,095.22 -9.9%

Range

₹1,089.44 – ₹1,095.47

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on ZYDUSLIFE, misses included

Neutral 28 Sep 2026 → now Scores 28 Oct 2026

₹1,215.00 → ₹1,215.00 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare